How big is Amphastar Pharmaceuticals, Inc.?

As of Jun 18, Amphastar Pharmaceuticals, Inc. has a market capitalization of $1.41 billion, with net sales of $730.65 million and a net profit of $141.63 million over the latest four quarters. The balance sheet shows shareholder's funds of $732.30 million and total assets of $1.62 billion.

As of Jun 18, Amphastar Pharmaceuticals, Inc. has a market capitalization of 1,413.88 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the company reported net sales of 730.65 million and a net profit of 141.63 million for the latest four quarters.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 732.30 million and total assets of 1,624.22 million.

What does Amphastar Pharmaceuticals, Inc. do?

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and sells generic and injectable products. As of March 2025, it reported net sales of $171 million and a net profit of $25 million, with a market cap of approximately $1.41 billion.

Overview:<BR>Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, markets, and sells generic and injectable, inhalation, and intranasal products, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 171 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 25 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,413.88 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 10.00 <BR>Debt Equity: 0.50 <BR>Return on Equity: 19.18% <BR>Price to Book: 1.88<BR><BR>Contact Details:<BR>Address: 11570 6th St, RANCHO CUCAMONGA CA: 91730-6025 <BR>Tel: 1 909 9809484 <BR>Website: http://www.amphastar.com

Who are in the management team of Amphastar Pharmaceuticals, Inc.?

As of March 2022, the management team of Amphastar Pharmaceuticals, Inc. includes Dr. Mary Luo (COO and Chairman), Mr. Jack Zhang (CEO), and several independent directors, including Mr. Richard Prins and Ms. Diane Gerst, overseeing the company's operations and strategy.

As of March 2022, the management team of Amphastar Pharmaceuticals, Inc. includes the following members:<BR><BR>- Dr. Mary Luo: Chief Operating Officer, Chief Scientist, and Chairman of the Board<BR>- Mr. Jack Zhang: President, Chief Executive Officer, Chief Scientific Officer, and Director<BR>- Mr. Richard Prins: Lead Independent Director<BR>- Ms. Diane Gerst: Director<BR>- Mr. Richard Koo: Independent Director<BR>- Dr. Howard Lee: Independent Director<BR>- Mr. Floyd Petersen: Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Should I buy, sell or hold Amphastar Pharmaceuticals, Inc.?

Is Amphastar Pharmaceuticals, Inc. overvalued or undervalued?

As of July 7, 2025, Amphastar Pharmaceuticals, Inc. is considered undervalued with a P/E ratio of 10 and an attractive valuation grade, despite a year-to-date return of -26.10% and a 1-year return of -44.88%, indicating a disconnect between its valuation metrics and market sentiment.

As of 7 July 2025, the valuation grade for Amphastar Pharmaceuticals, Inc. moved from expensive to attractive, indicating a shift towards a more favorable assessment. The company appears undervalued based on its current metrics, with a P/E ratio of 10, a Price to Book Value of 1.91, and an EV to EBITDA of 7.14. In comparison, peers like Prestige Consumer Healthcare, Inc. have a P/E of 15.85 and an EV to EBITDA of 11.55, while Corcept Therapeutics, Inc. is considered very expensive with a P/E of 60.03.<BR><BR>Despite the attractive valuation, Amphastar has struggled in recent performance, with a year-to-date return of -26.10% compared to the S&P 500's positive return of 12.22%. This underperformance over the past year, alongside a 1-year return of -44.88%, suggests that while the stock may be undervalued, market sentiment has not yet aligned with its valuation metrics.

Is Amphastar Pharmaceuticals, Inc. technically bullish or bearish?

As of October 31, 2025, Amphastar Pharmaceuticals shows a mildly bullish trend, but mixed technical indicators and significant underperformance against the S&P 500 suggest caution.

As of 31 October 2025, the technical trend for Amphastar Pharmaceuticals, Inc. has changed from sideways to mildly bullish. However, the overall technical indicators present a mixed picture. The MACD is bearish on both weekly and monthly timeframes, while the RSI shows no signal. Moving averages are bearish on a daily basis, and the KST is mildly bearish weekly and bearish monthly. Dow Theory indicates a mildly bullish stance on the weekly timeframe but shows no trend monthly. <BR><BR>Despite the recent mild bullish trend, the stock has underperformed significantly against the S&P 500 across multiple periods, with a year-to-date return of -31.97% compared to the S&P's 16.30%, and a one-year return of -50.21% versus 19.89% for the index. Overall, the technical stance is mildly bullish but weak, with key indicators suggesting caution.